Clinical research progress on drugs against SARS-CoV-2
10.13200/j.cnki.cjb.003873
- VernacularTitle:抗SARS-CoV-2药物的临床研究进展
- Author:
QUAN Jiali
- Publication Type:Journal Article
- Keywords:
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2);
Coronavirus Disease 2019(COVID-19);
Therapeutic drugs;
Monoclonal antibody;
Small-molecular drug
- From:
Chinese Journal of Biologicals
2023;36(4):469-
- CountryChina
- Language:Chinese
-
Abstract:
The rapid spread of Coronavirus Disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection has had a devastating impact on public health and the global economy. Tremendous efforts had been put on urgent development of prophylactic or therapeutic drugs against SARS-CoV-2,mainly smallmolecule antiviral drugs and monoclonal antibodies,to reduce the impact and burden of COVID-19. Currently,National Medical Products Administration(NMPA)of China or Food and Drug Administration(FDA)of the United States have approved three small-molecule drugs and three monoclonal antibodies for use. This paper reviews the clinical research progress and challenges of the main drugs against SARS-CoV-2 on the market at present.
